DMK PHARMACEUTICALS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.035 USD | -2.78% |
|
-30.42% | -95.00% |
| Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 146.9 | 106.4 | 43.17 | 45.43 | 90.08 | 25.39 |
| Enterprise Value (EV) 1 | 134.6 | 89.72 | 38.44 | 45.44 | 69.55 | 24.96 |
| P/E ratio | -4.88 x | -2.25 x | -1.27 x | -0.76 x | -1.9 x | -0.96 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 11.2 x | 7.05 x | 1.95 x | 2.75 x | 40.8 x | 5.34 x |
| EV / Revenue | 10.3 x | 5.95 x | 1.74 x | 2.75 x | 31.5 x | 5.25 x |
| EV / EBITDA | -6.22 x | -2.47 x | -1.46 x | -1.35 x | -2.27 x | -1.06 x |
| EV / FCF | -19.6 x | -4.89 x | -3.11 x | -5.27 x | -2.14 x | -2.62 x |
| FCF Yield | -5.1% | -20.5% | -32.2% | -19% | -46.7% | -38.2% |
| Price to Book | 3.71 x | 2.28 x | 1.2 x | 13 x | 3.5 x | -31.4 x |
| Nbr of stocks (in thousands) | 477 | 676 | 880 | 1,338 | 2,127 | 2,143 |
| Reference price 2 | 308.0 | 157.5 | 49.03 | 33.96 | 42.35 | 11.85 |
| Announcement Date | 3/16/18 | 3/15/19 | 3/30/20 | 4/15/21 | 3/31/22 | 3/16/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 13.07 | 15.09 | 22.11 | 16.53 | 2.209 | 4.756 |
| EBITDA 1 | -21.63 | -36.35 | -26.41 | -33.67 | -30.63 | -23.58 |
| EBIT 1 | -24.69 | -39.45 | -29.35 | -37.23 | -32.07 | -25.06 |
| Operating Margin | -188.88% | -261.51% | -132.72% | -225.25% | -1,451.97% | -526.88% |
| Earnings before Tax (EBT) 1 | -25.88 | -39.38 | -29.3 | -49.39 | -34.6 | -26.2 |
| Net income 1 | -25.54 | -39.01 | -29.31 | -49.39 | -45.83 | -26.48 |
| Net margin | -195.35% | -258.55% | -132.53% | -298.84% | -2,074.91% | -556.72% |
| EPS 2 | -63.06 | -69.86 | -38.52 | -44.57 | -22.25 | -12.37 |
| Free Cash Flow 1 | -6.861 | -18.37 | -12.37 | -8.623 | -32.49 | -9.533 |
| FCF margin | -52.48% | -121.73% | -55.94% | -52.17% | -1,470.86% | -200.43% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/16/18 | 3/15/19 | 3/30/20 | 4/15/21 | 3/31/22 | 3/16/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Net sales | 0.76 | -1.159 | 1.155 | 0.0398 | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT | -10.22 | -7.916 | -7.913 | -8.176 | - | - |
| Operating Margin | -1,344.89% | 682.79% | -685.42% | -20,516.74% | - | - |
| Earnings before Tax (EBT) | -5.168 | -7.812 | -10.19 | -8.397 | - | - |
| Net income 1 | -12.36 | -8.774 | -10.35 | -8.397 | -4.399 | -1.388 |
| Net margin | -1,626.54% | 756.76% | -896.88% | -21,072.07% | - | - |
| EPS 2 | -5.600 | -4.200 | -4.900 | -4.200 | -2.100 | -0.2000 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/22/21 | 3/31/22 | 5/16/22 | 8/10/22 | 11/14/22 | 11/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 0 | - | - |
| Net Cash position 1 | 12.3 | 16.7 | 4.73 | - | 20.5 | 0.43 |
| Leverage (Debt/EBITDA) | - | - | - | -0.000093 x | - | - |
| Free Cash Flow 1 | -6.86 | -18.4 | -12.4 | -8.62 | -32.5 | -9.53 |
| ROE (net income / shareholders' equity) | -78.8% | -90.5% | -70.8% | -271% | -236% | -208% |
| ROA (Net income/ Total Assets) | -34.6% | -44.9% | -34.5% | -59.1% | -58% | -63.6% |
| Assets 1 | 73.8 | 86.82 | 84.83 | 83.54 | 79.07 | 41.61 |
| Book Value Per Share 2 | 82.90 | 69.10 | 40.80 | 2.610 | 12.10 | -0.3800 |
| Cash Flow per Share 2 | 36.30 | 28.50 | 9.970 | 5.110 | 10.90 | 0.5000 |
| Capex 1 | 2.06 | 3.54 | 2.87 | 0.7 | 1.22 | 0.68 |
| Capex / Sales | 15.78% | 23.43% | 12.96% | 4.21% | 55.39% | 14.31% |
| Announcement Date | 3/16/18 | 3/15/19 | 3/30/20 | 4/15/21 | 3/31/22 | 3/16/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -95.00% | 353K | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DMKPQ Stock
- Financials DMK Pharmaceuticals Corporation
